The “Brain Insurance” Myth

If you walk into any health food store today, you’ll see aisles dedicated to Omega-3 supplements. They’re sold as ‘brain insurance’ — the idea that a few capsules a day can shield you from Alzheimer’s, or other forms of cognitive decline and dementia.

It’s a multi-billion-dollar industry built on a foundation of some admittedly promising science. But lately, the narrative has started to shift. We’re seeing large-scale meta-analyses that don’t quite back up the hype. “Meta-analyses” are large studies that combine many clinical trials.

 A few recent studies suggest we might actually be taking risks that we didn’t “sign up” for.

Today, I want to walk through some of the actual data — looking at four major clinical reviews, and one specific warning — to get a better handle on whether fish oil is actually protecting our brains, or if you’re just wasting our money on (potentially rancid) piscine oil.

This isn’t medical advice — just a look at what the current evidence actually says. 

The Core Theory: Why We Care About DHA

To understand why we’re even talking about this, we have to look at what your brain is made of. 

About 60% of your gray matter is fat — by dry weight. And a huge portion of that is a specific Omega-3 fatty acid called docosahexaenoic (/duh-KOH-suh hek-suh-NOH-ick/) acid, or “DHA.”

Think of DHA as a key structural and functional component of neuronal membranes.

According to a 2018 update on Omega-3s and Alzheimer’s [Source 3], these fats do two main things. 

Firstly, they keep your cell membranes fluid. These membranes have to be flexible to stay functional when it comes to immune response, nerve signaling, and nutrient transport. 

And, secondly, DHA fats act as powerful anti-inflammatories.

Early on, Alzheimer’s is often described as ‘low-grade’ inflammation — like a fire smoldering under the surface. But over time, that can escalate into something sustained and destructive that doesn’t fully resolve..

On paper, Omega-3s should help calm that process.

And, in laboratory and animal studies, Omega-3 has been shown to reduce amyloid-beta accumulation — the plaques long considered hallmarks of the disease.

Though, as we’ll explore in a future video, it’s worth noting that the amyloid hypothesis itself has taken some serious hits recently, including high-profile controversies over foundational research. The science isn’t as settled as supplement labels would have you believe.

And, as we’ve learned in medicine, what happens in a petri dish doesn’t always happen in a human being. Indeed, the “low-grade” label is increasingly being considered an oversimplification.

That said, none of this has stopped supplement suppliers from making promises about fish oil — promises that, as we’ll see, the clinical data doesn’t fully back up.

The Reality Check: What the Data Says

This is where the “matter-of-fact” reality hits. I looked at a systematic review of over a dozen clinical trials [Source 1] and a landmark PubMed review [Source 2] to see if fish-oil supplements actually halt the sort of brain inflammation that develops into full-blown dementia.

Here is the honest breakdown.

If you have, or your loved one has, already gotten a diagnosis of Alzheimer’s Disease, then the supplements don’t seem to do much. The data shows no significant reversal of cognitive decline once the disease is established.

However — and this is a big “however” — some researchers have identified what they call a “window of opportunity.” The stronger evidence points to earlier intervention — pre-clinical stages, or mild cognitive impairment — not after diagnosis.

We’re talking about people with Mild Cognitive Impairment (“MCI”) or people who are cognitively healthy but have a genetic risk, like the APOE4 gene — a genetic variant linked to higher Alzheimer’s risk — which we have gotten into in a previous video.

So, if you’re waiting for memory loss to start before you take your brain health seriously, you’ve likely missed the boat for Omega-3s to be effective. 

If it’s anything, it’s better thought of as a preventative tool, not a rescue medication.

And even in studies that do show benefits, the effects tend to be modest — not dramatic. 

The Metric: “Test, Don’t Guess”

One of the biggest reasons people see mixed results is that they aren’t actually measuring if the supplement is working. A paper in the journal American Journal of Clinical Nutrition [Source 4] argues that we should be focusing on something called the Omega-3 Index.

Most people just take a pill and hope for the best. But everyone absorbs fats differently. The Omega-3 Index is a blood test. It measures how much EPA and DHA are actually built into your red blood cells — which reflects long-term intake. 

An index of ~8% or higher is the established cardiovascular target; brain health research is pointing in the same direction, though that threshold isn’t yet definitive.

If you’re taking a low-quality supplement or your body isn’t absorbing it well, you might still be at a 4% or 5% index — which is basically a deficiency zone.

If you aren’t testing your levels, you’re essentially flying blind. You might be taking a dose that’s too low to matter, or wasting money on a supplement your body isn’t even processing.

You can’t improve what you don’t track.

The Potential Problem: Oxidation and AFib

Now, we should address the “red flag” that’s been popping up in recent headlines. 

A report from SciTechDaily [Source 5] highlighted a potential risk that many supplement companies don’t want to talk about: Oxidation.

Fish oil can be unstable. There’s concern that poorly stored or low-quality fish oil may oxidize  or, to put it more dramatically, the worry is that it could go rancid when exposed to heat, light, or air. 

Plainly, if it turned out that you were swallowing oxidized fish oil, then you wouldn’t be reducing inflammation — you’d potentially be introducing oxidative stress into your system.

But there’s a more specific medical concern. Recent data has linked high-dose fish oil supplementation to an increased risk of Atrial Fibrillation, or AFib — which is an irregular heart rhythm that can lead to strokes.

Now, I want to be careful with my language here, because this finding doesn’t quite fit the definition of an “outlier” that some have used to describe it. An outlier is a single anomalous data point. The AFib signal isn’t that — it has shown up across multiple large clinical trials, which actually makes it a replicated finding. That’s more serious, not less. The supplement industry might prefer you think of this as a fringe result. It isn’t.

This risk appears more pronounced at higher doses and in certain populations.

For example, in this case, the data suggests that “megadosing” fish oil — say, taking 4 or 5 grams a day without a doctor’s supervision — might be creating cardiovascular risks that outweigh the potential brain benefits, especially if you aren’t actually deficient to begin with. Which — again — you won’t know until your levels are measured.

And, to be fully transparent, some risk signals have appeared at lower doses too, particularly in prescription-grade formulations. 

The honest bottom line is that the dose threshold isn’t perfectly established yet. Which is all the more reason to loop in your doctor before you dramatically increase your intake.

So yes — there’s a real risk conversation to have here, particularly around dose. But risk in context isn’t the same as “don’t bother.” It just means: be deliberate.

Conclusion: The Pragmatic Approach

So where does that leave us?

Omega-3s clearly matter for brain structure — but supplements aren’t a magic solution.

If you’re thinking about using them, a more grounded approach looks like this:

First: prioritize food. Fatty fish like sardines, mackerel, and salmon provide Omega-3s in a more stable, nutrient-rich form.

Second: if you do supplement, be picky. Fish oil is fragile — and quality matters. Choose third-party tested products. Look for labels like the dedicated, so-called “International Fish Oil Standards” program, or “IFOS” (/EYE-fohs/). And… If it smells off, don’t use it.

And third: know your numbers. The Omega-3 Index can tell you whether you’re actually in an meaningful range — or just guessing.

Because in the end, brain health isn’t about one supplement. It’s about maintaining the integrity of your brain over decades.

Fish oil may be one tool — but it’s not the whole toolbox.

If you found this helpful, consider subscribing for future breakdowns like this. And feel free to share it with someone who might benefit.

And, as always, we wish you all the best with your Alzheimer’s-proofing journey. Thanks for watching.

Sources:

[1]: https://pubmed.ncbi.nlm.nih.gov/28986068/ “Effectiveness of omega-3 fatty acid supplementation in patients with Alzheimer disease: A systematic review and meta-analysis – PubMed”

[2]: https://pubmed.ncbi.nlm.nih.gov/19523795/ “Omega-3 fatty acids and dementia – PubMed”

[3]: https://pubmed.ncbi.nlm.nih.gov/30084334/ “A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease – PubMed”

[4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9761771/ “The omega-3 index in Alzheimer’s disease: Ready for prime time? – PMC”

[5]: https://scitechdaily.com/scientists-uncover-potential-brain-risks-of-popular-fish-oil-supplements/

Given the research we do for this channel, I am no stranger to surprising, sometimes controversial—and occasionally disgusting—claims regarding Alzheimer’s disease.

In a previous video, we explored how something as mundane as earwax buildup—or, more technically, cerumen impaction—could lead to hearing loss and, by extension, cognitive decline.

Today, we’re looking at a physical habit.

It’s often dismissed as a minor social faux pas—and was even the subject of jokes in an old Seinfeld episode. But recent research suggests this common behavior might create a pathway for certain pathogens to reach the brain.

We’re talking about nose-picking—and its potential link to late-onset dementia.

For the companion video, see here:

The Griffith University Study

A team of researchers at Griffith University in Australia published a 2022 study in the journal Scientific Reports. They focused on a bacterium called Chlamydia pneumoniae.

This common airborne bacterium—sometimes called the Taiwan Acute Respiratory Agent—is primarily known for causing bronchitis and pneumonia. However, it has also been detected in a significant number of human brains affected by late-onset dementia.

Using mouse models, the researchers tracked how this bacterium travels. What they found was striking: it can move along the olfactory nerve—from the nasal cavity directly into the brain.

In these models, infection reached the central nervous system within 24 to 72 hours. Once inside, it triggered amyloid-beta deposition—the same protein associated with Alzheimer’s plaques.

One interpretation is that amyloid-beta may function as part of the brain’s immune response to infection. However, if that infection becomes chronic or repeatedly facilitated—potentially through damage to the nasal lining—this process could contribute to neurodegeneration.

In short: this research suggests that certain behaviors might make it easier for pathogens to access the brain.

Connection: The Earwax Analogy

You may remember from our earwax discussion that conductive hearing loss involves a physical obstruction—something like earwax blocking sound transmission.

In a similar way, the nasal epithelium acts as both a physical and immunological barrier.

The Griffith University study found that when this barrier was damaged, infections in the mice became significantly more severe.

Think of the nasal lining as a security checkpoint: if it’s intact, most threats are stopped. If it’s compromised, things can slip through.

Just as we cautioned against inserting objects into the ear canal, scientists now warn that picking—or plucking nose hairs—can damage this delicate lining. That damage may give pathogens a clearer route to the brain.

Why This Matters

As geriatrician Maria Carney noted in our earwax discussion, “most people don’t even realize that they have an issue.”

That lack of awareness is a recurring theme in both Alzheimer’s prevention and detection.

While nose-picking is often associated with children, it remains common in adults. In fact, one study found that about 91% of people admit to it.

I’m curious how that compares with this audience—so I’ve put up an anonymous poll if you’d like to weigh in.

As many viewers know, age alone—especially over 65—significantly increases Alzheimer’s risk.

If we add environmental exposures, such as introducing pathogens through repeated nasal damage, this could represent an additional, potentially modifiable risk factor.

Caveats and Disclaimers

To be clear: this is early-stage research conducted in mice. We do not yet have direct evidence that this pathway operates the same way in humans.

Human trials would be needed to confirm whether a similar mechanism is at work.

And of course, Alzheimer’s disease likely involves multiple contributing factors—including acetylcholine loss, plaque formation through other mechanisms, neurofibrillary tangles, and nutritional or metabolic influences.

So yes—this hypothesis may sound farfetched.

But it is being seriously explored, and it may be worth paying attention to.

Practical Advice and Conclusion

One of the core goals of the Alzheimer’s Proof project is prevention. And unfortunately, there is no single solution—no magic bullet.

What we can do is try to stack the odds in our favor.

Protect the Barrier

Avoid plucking nose hairs and minimize behaviors that could damage the nasal lining. Chronic irritation may increase vulnerability.

Use Safer Alternatives

If needed, consider electric trimmers for grooming. For congestion, saline sprays or nasal irrigation may help. If using a neti pot, always use distilled or properly purified water.

Keep It Clean

If you must manually clear your nose, ensure your hands are clean—before and after. Also keep fingernails trimmed and smooth to reduce the risk of micro-injury.

Stay Aware

Consult a healthcare provider if you experience persistent irritation, bleeding, or signs of infection.

The key takeaway here isn’t panic—it’s awareness.

Small habits, repeated over time, can shape long-term brain health.

And if reducing Alzheimer’s risk comes down—even in part—to eliminating preventable factors, then even small changes may be worth considering.

________________________________________

References:

• David Nield, “Nose-Picking May Have a Surprise Link With Alzheimer’s, Study in Mice Suggests,” Science Alert, April 5, 2026, <https://www.sciencealert.com/nose-picking-may-have-a-surprise-link-with-alzheimers-study-in-mice-suggests>. 
  
• Anu Chacko, Ali Delbaz, Heidi Walkden, Souptik Basu, Charles W. Armitage, Tanja Eindorf, Logan K. Trim, Edith Miller, Nicholas P. West, James A. St John, Kenneth W. Beagley, and Jenny A. K. Ekberg, “Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer’s disease risk,” Scientific Reports, vol. 12, no. 2759, February 17, 2022, <https://www.nature.com/articles/s41598-022-06749-9>. 

• “Can Earwax Buildup Cause Memory Loss? Cerumen Impaction & Dementia,” video, Alzheimer’s Proof (YouTube), Oct 24, 2020, <https://www.youtube.com/watch?v=OVnZJuM__mc>.

AT A GLANCE: Amyloid‑β plaques = a hallmark of Alzheimer’s disease; Most drugs target plaques directly

Alzheimer’s may involve a failure of brain “cleanup,” not just toxic buildup.

What if Alzheimer’s isn’t just caused by toxic buildup in the brain — but by the brain’s own cleanup crews being quietly dismantled from the inside?

If you’ve been around the block, when it comes to Alzheimer’s, you probably realize that a primary “pathological hallmark” is the accumulation of – what are called – “amyloid-beta plaques” within the brain.

• AT A GLANCE: What if the problem is impaired clearance—not just plaque formation?

For over a century — since Alzheimer’s was first described in 1906 — drug development has largely focused on stopping plaque formation or clearing plaques after they appear.

And a critical area of this investigation involves taking a close look at the brain’s innate ability to clear these toxic proteins.

Recent research from the Indiana University School of Medicine has identified a specific enzyme that, when it is present, appears to be a factor when someone’s brain-clearing mechanisms go haywire.

And, in this video, we’ll look at a CliffsNotes’ version of the results.

https://www.youtube.com/embed/t0G-diPs2yU?si=lXQ5cl1JulI-IZmt

• AT A GLANCE: IDOL = Inducible Degrader of the LDL receptor controls how many LDL receptors remain on brain cells

The enzyme is abbreviated I‑D‑O‑L, or “IDOL,” short for “Inducible Degrader of the LDL receptor.” That expression (a mouthful, for sure) designates a protein that controls how many LDL receptors survive on the surface of brain cells.

But… what the heck is it? And, more importantly, how would its inhibition (quote, unquote) represent a promising shift in doctors might approach Alzheimer’s treatments?

The Molecular Rôle of “IDOL”

• AT A GLANCE: Receptors = cellular “locks” that trigger actions

To even begin to understand this discovery — and to be perfectly honest, that’s about the most ambitious goal I can realistically aim for — we need to talk about something called a low‑density lipoprotein, or “LDL,” receptor.

First, in the relevant context, a “receptor” is a protein on a cell — or in a cell — that acts like a lock. When the right chemical “key” comes along, that lock opens and tells the cell to do… something.

• AT A GLANCE: LDL receptors pull material into cells for use or disposal

An LDL receptor is one of these locks. Its job is to grab so‑called “bad” cholesterol — LDL — and pull it into cells so it can be used or gotten-rid-of.

Think of it like a trash‑pickup claw that grabs garbage from the streets of the body and pulls it inside for disposal.

• AT A GLANCE: In the brain, LDL receptors help manage APOE and amyloid‑β

In the central nervous system, LDL receptors also play a crucial role in regulating APOE, a protein involved in the transport and clearance of amyloid‑beta.

So far, so good?

• AT A GLANCE: IDOL tags LDL receptors for destruction

Now for this IDOL business.

IDOL is not a receptor itself. It’s a protein that comes along and “tags” LDL receptors for destruction — that’s the “inducible degrader” part of its full name.

• AT A GLANCE: Overactive IDOL à fewer LDL receptors; (-) Amyloid clearance à (+) plaque buildup

It’s like removing the trash‑pickup claws and throwing them away instead of the “bad” cholesterol. Reducing the number of LDL receptors on cell surfaces is a bit like getting rid of trash trucks in the heart of a crowded city. It’s not good.

When IDOL becomes overactive, too many LDL receptors are destroyed, weakening the brain’s ability to clear APOE and toxic amyloid‑beta proteins. This allows plaques to accumulate and neurodegeneration to accelerate.

In effect, an overactive cellular “shutdown switch” disables the brain’s cleanup crews at precisely the moment they’re needed most.

Receptor Inhibitors — and Why IDOL Is Different

• AT A GLANCE: IDOL inhibitors protect receptors; They stop destruction — not signaling

At this point, it helps to understand what scientists mean by a “receptor inhibitor.” Usually, a receptor inhibitor blocks a lock so that even when the correct key shows up, the cell can’t respond. But that’s not quite what’s happening here.

An IDOL inhibitor doesn’t block the lock — it stops the demolition crew from tearing the lock off the door. In other words, inhibiting IDOL prevents LDL receptors from being destroyed, allowing the brain’s cleanup machinery to stay in place and keep doing its job.

IDOL Proteins Aren’t the Problem in and of Themselves

Let’s register a couple caveats.

Number one, it’s important to understand that IDOL proteins aren’t “bad” in and of themselves. They’re normal control mechanisms within the complex anatomy-biology of the body.

And they don’t come from “outside.” Your own cells make IDOL proteins automatically.

• AT A GLANCE: IDOL is a normal control mechanism; Problems arise when it shuts things down too aggressively

Think of their part in in the trash-removal process as akin to that of a “thermostat” that off the air conditioner or furnace when the desired temperature is reached.  When a cell thinks it’s cleaned up enough LDL cholesterol, these IDOL proteins shut down the whole process.

In the context of Alzheimer’s Disease, overactive IDOL proteins lead to a depletion of these trash-removal receptors. In turn, this loss diminishes the brain’s capacity to clear amyloid-beta. And that, researchers, suspect, leads to – or makes worse – the formation of the plaques that lead to neurodegeneration.

Whew!

• AT A GLANCE: Evidence so far: animal + cellular studies

It’s also important to note that this entire IDOL–LDL receptor mechanism has been demonstrated primarily in animal and cellular studies. While the evidence strongly implicates IDOL in Alzheimer’s pathology, human treatments are still in-process.

Research Findings

Neuronal vs. Microglial IDOL

AT A GLANCE: Microglial IDOL removal à little effect; Neuronal IDOL removal à major plaque reduction]

The study in question was led by Dr. Hande Karahan and Dr. Jungsu Kim, who sought to determine which cell types were most responsible for IDOL-mediated damage. Historically, the scientific community focused on microglia — the brain’s immune cells — as the primary drivers of plaque-clearance.

However, using a series of “knockout models,” the Indiana University team found that removing IDOL from microglia had a negligible effect on plaque levels.

• AT A GLANCE: “Knockout” = a gene deliberately switched off to study its function

A “knockout model” is a genetically engineered animal — usually a mouse — in which a gene like IDOL is “switched off” so scientists can see how the brain behaves without it.

They take out a gene to see what breaks — or improves — when it’s gone.

When IDOL was “deleted” specifically from neurons, the results were deemed significant. The researchers observed a substantial reduction in amyloid-beta deposition.

• AT A GLANCE: Lower APOE4 levels observed; APOE4 = strongest genetic risk factor for late‑onset Alzheimer’s

Additionally, the deletion of neuronal IDOL led to a decrease in APOE4 levels. As APOE4 is the most significant genetic risk factor for late-onset Alzheimer’s, this suggests that targeting IDOL could directly mitigate the risks associated with this specific genotype.

Clinical Implications and Synaptic Health

• AT A GLANCE: IDOL inhibition linked to improved ‘synaptic plasticity’; Healthier connections = better learning & memory support

What distinguishes this research from current treatments — such as antibodies that target existing plaques — is its focus on enhancing the brain’s internal environment.

The researchers also observed a second effect – beyond reducing toxic amyloid-beta. This is to say that inhibiting IDOL was also associated with improvements in synaptic plasticity — the brain’s ability to adjust and strengthen connections involved in learning and memory.

It refers to how the brain “rewires” itself.

Conclusion: The Path to Small-Molecule Therapeutics

• AT A GLANCE: Targeting IDOL may improve the brain’s internal environment

From a pharmaceutical perspective, the IDOL enzyme is a highly viable (read: commercially promising) target.

So, the upshot is that drug-researchers believe they may be able to engineer an oral medication capable of inhibiting the trash-removal inhibition!

• AT A GLANCE: Goal: oral drugs that cross the blood‑brain barrier; Less invasive than antibody infusions

From a cost-per-treatment standpoint, this would an advancement over the current method, which requires expensive – and invasive – intravenous infusions required to deliver antibody treatments to try to dissolve plaques.

The Indiana University School of Medicine team is still a “preclinical” phase. Its focus is on screening for “small molecules” that can effectively cross the blood-brain barrier to inhibit IDOL. While further trials are obviously necessary, this research provides a roadmap for a new generation of Alzheimer’s therapies.

For those you still here, thank you for sticking with it! I know it was heavy-going.

If you’d like to dig deeper, here’s a link to the original study — because this is one of those cases where the data itself really is the story.